KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Other Non-Current Liabilities (2019 - 2025)

Esperion Therapeutics (ESPR) has disclosed Other Non-Current Liabilities for 7 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $8.7 million, compared with a TTM value of $8.7 million through Dec 2025, changed N/A, and an annual FY2025 reading of $8.7 million, changed N/A over the prior year.
  • Other Non-Current Liabilities was $8.7 million for Q4 2025 at Esperion Therapeutics, up from $7.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $265.0 million in Q3 2022 and bottomed at $1.3 million in Q1 2021.
  • Average Other Non-Current Liabilities over 5 years is $166.6 million, with a median of $232.0 million recorded in 2021.
  • The sharpest move saw Other Non-Current Liabilities crashed 99.18% in 2021, then soared 19588.14% in 2022.
  • Year by year, Other Non-Current Liabilities stood at $245.7 million in 2021, then decreased by 10.95% to $218.8 million in 2022, then rose by 9.64% to $240.0 million in 2023, then decreased by 1.48% to $236.4 million in 2024, then tumbled by 96.3% to $8.7 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for ESPR at $8.7 million in Q4 2025, $7.4 million in Q3 2025, and $7.4 million in Q2 2025.